GenMark

The test completes a suite of assays designed to detect pathogens that can cause sepsis using the firm's ePlex system.

Natera and Veracyte both received positive news regarding local coverage determinations from Medicare contractors, while the catalysts for Fluidigm's rise were unclear.

The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.

The firm used about $38.8 million on Feb. 1 to repay all outstanding principal, interest, related fees, and other obligations under an existing loan agreement.

Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.

The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

The firm had also applied for marketing clearance for its gram negative and fungal pathogen panels in October.

After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.

The firm beat analysts' revenue expectations for the quarter while its net loss was in line with predictions.